Aytu BioPharma, Inc. (LON:0A8M)
London · Delayed Price · Currency is GBP · Price in USD 2.200
+0.520 (30.95%)
At close: May 16, 2025
Aytu BioPharma Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 62.64 | 66.38 | 65.18 | 73.8 | 96.67 | 65.63 | |
Revenue Growth (YoY) | 2.00% | 1.84% | -11.68% | -23.66% | 47.29% | 137.52% |
Cost of Revenue | 20.77 | 20.55 | 16.13 | 21.57 | 46.39 | 36.43 |
Gross Profit | 41.87 | 45.83 | 49.05 | 52.23 | 50.28 | 29.2 |
Selling, General & Admin | 39.09 | 38.29 | 42.04 | 49.77 | 69.88 | 55.81 |
Research & Development | 0.38 | 1.33 | 2.77 | 3.98 | 12.66 | 5.62 |
Amortization of Goodwill & Intangibles | 2.81 | 3.68 | 3.68 | 3.69 | 5.84 | 6.01 |
Operating Expenses | 42.28 | 43.29 | 48.49 | 57.44 | 88.39 | 67.44 |
Operating Income | -0.41 | 2.54 | 0.57 | -5.21 | -38.1 | -38.24 |
Interest Expense | -2.71 | -3.7 | -5.06 | -5.15 | -0.01 | -0.01 |
Other Non Operating Income (Expenses) | -12.86 | -2.22 | -3.13 | 5.22 | 0.86 | -2.04 |
EBT Excluding Unusual Items | -15.98 | -3.38 | -7.63 | -5.14 | -37.26 | -40.29 |
Merger & Restructuring Charges | - | -2.1 | -2.16 | - | - | -7.81 |
Impairment of Goodwill | - | - | - | - | -65.8 | - |
Asset Writedown | -8.26 | -8.26 | - | -2.73 | -7.66 | -12.83 |
Other Unusual Items | - | - | -0.59 | 0.58 | 1.82 | 2.89 |
Pretax Income | -24.24 | -13.75 | -10.38 | -7.29 | -108.89 | -58.03 |
Income Tax Expense | 0.32 | 0.44 | 2.14 | 0.26 | -0.11 | 0.26 |
Earnings From Continuing Operations | -24.56 | -14.18 | -12.52 | -7.55 | -108.78 | -58.29 |
Earnings From Discontinued Operations | 0.12 | 0.62 | -3.32 | -9.5 | - | - |
Net Income | -24.44 | -13.56 | -15.84 | -17.05 | -108.78 | -58.29 |
Net Income to Common | -24.44 | -13.56 | -15.84 | -17.05 | -108.78 | -58.29 |
Shares Outstanding (Basic) | 8 | 6 | 6 | 3 | 1 | 1 |
Shares Outstanding (Diluted) | 8 | 6 | 6 | 3 | 1 | 1 |
Shares Change (YoY) | 38.73% | 13.40% | 65.81% | 127.22% | 75.54% | 270.57% |
EPS (Basic) | -3.02 | -2.16 | -2.86 | -5.11 | -74.01 | -69.61 |
EPS (Diluted) | -3.02 | -2.16 | -2.86 | -5.11 | -74.01 | -69.61 |
Free Cash Flow | -0.7 | -2.17 | -1.72 | -5.13 | -28.82 | -28.31 |
Free Cash Flow Per Share | -0.09 | -0.34 | -0.31 | -1.54 | -19.61 | -33.80 |
Gross Margin | 66.84% | 69.04% | 75.26% | 70.77% | 52.02% | 44.49% |
Operating Margin | -0.66% | 3.82% | 0.87% | -7.05% | -39.42% | -58.26% |
Profit Margin | -39.02% | -20.43% | -24.31% | -23.11% | -112.53% | -88.81% |
Free Cash Flow Margin | -1.11% | -3.26% | -2.63% | -6.95% | -29.82% | -43.13% |
EBITDA | 4.03 | 7.91 | 7.29 | 2.49 | -27.96 | -29.04 |
EBITDA Margin | 6.43% | 11.92% | 11.18% | 3.38% | -28.92% | -44.25% |
D&A For EBITDA | 4.44 | 5.38 | 6.73 | 7.7 | 10.15 | 9.2 |
EBIT | -0.41 | 2.54 | 0.57 | -5.21 | -38.1 | -38.24 |
EBIT Margin | -0.66% | 3.82% | 0.87% | -7.05% | -39.42% | -58.26% |
Advertising Expenses | - | - | - | - | 13.6 | 15.2 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.